openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Viatris Inc. (NASDAQ: VTRS) over potential Wrongdoing

An investigation on behalf of current long term investors in Viatris Inc. (NASDAQ: VTRS) shares.

An investigation on behalf of current long term investors in Viatris Inc. (NASDAQ: VTRS) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Viatris Inc.

Investors who are current long term investors in Viatris Inc. (NASDAQ: VTRS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in Viatris Inc. (NASDAQ: VTRS stocks follows a lawsuit filed against Viatris Inc. (NASDAQ: VTRS over alleged securities laws violations. The investigation on behalf of current long term investors in Viatris Inc. (NASDAQ: VTRS stocks, concerns whether certain Viatris Inc. (NASDAQ: VTRS officers and directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Western District of Pennsylvania the plaintiff alleges that Viatris made materially false and/or misleading statements and/or failed to disclose that the Company was experiencing significantly more competition in its United States complex generics business than disclosed, that the Company was not able to effectively manage its base business erosion or create a stable revenue base, that despite being on the Company's only growth drivers, Viatris was actively planning to divest its biosimilars business in order to secure enough cash to let it purportedly meet its phase one goals, that Viatris was deviating from the business model it touted throughout the Class Period and undertaking a significant global reshaping of its business which would undermine its ability to achieve stable revenue growth, and that the Company was anticipating less financial growth moving into 2022.

Those who purchased shares of Viatris Inc. (NASDAQ: VTRS) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
Web: www.shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Viatris Inc. (NASDAQ: VTRS) over potential Wrongdoing here

News-ID: 4087310 • Views:

More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for long term investors in
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ: FTNT)
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on October 07, 2025
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc. Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR)
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Viatris

Abacavir Market is Booming Worldwide with GlaxoSmithKline, Viatris, Cipla
The latest study released on the Global Abacavir Market by HTF MI evaluates market size, trend, and forecast to 2031. The Abacavir market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Key Players in This Report
Naloxone Market Growth in Future Scope 2024-2031 | Akorn, Inc, Hikma Pharmaceuti …
The Latest research report on the Naloxone Market 2024 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2031. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Naloxone Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies, market dynamics, cost structures,
Influenza Vaccines Industry May See a Big Move | BIKEN, Viatris, Sinovac Biotech
Data Insights Market published a new research publication on "Influenza Vaccines Industry Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Influenza Vaccines Industry was mainly driven by the increasing R&D spending across the world. Some of the key players profiled in
Motion Sickness Drugs Market Is Booming Worldwide | Hylands,Perrigo, Viatris
The "Motion Sickness Drugs Market" intelligence report, just published by USD Analytics Market, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Motion Sickness Drugs Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major
Complex Regional Pain Syndrome Market Key Players | GlaxoSmithKline plc., Johnso …
As per the study initiated by Evolve Business Intelligence, the global Complex Regional Pain Syndrome Market size accounted for USD 102.3 Million in 2022, growing at a CAGR of 2.2% from 2023 to 2033. Complex Regional Pain Syndrome (CRPS) Market refers to the economic landscape associated with the diagnosis, treatment, and management of Complex Regional Pain Syndrome. CRPS is a chronic condition characterized by severe and prolonged pain, usually in
Pulmonary Arterial Hypertension Market Is Booming Worldwide with Bayer, Sandoz, …
Pulmonary Arterial Hypertension Market latest research report added by USD Analytics. The Pulmonary Arterial Hypertension Market Study has been segmented by key a region that is accelerating the marketization. The report is a great blend of qualitative and quantitative market data that was gathered and evaluated mostly through primary data and secondary sources. This also provides the scope of different segments and applications that can potentially influence the marketplace in